Cleveland BioLabs is a cutting-edge brand that specializes in developing novel immunotherapies to target a wide range of diseases. With a focus on autoimmune diseases, infectious diseases, inflammatory diseases, and cancers, Cleveland BioLabs offers innovative solutions to combat these health challenges. Their flagship program, the Advanced Immunomodulating Multi-receptor System (AIMS), delivers immune homeostasis through second-generation immune therapies.

By using a multi-receptor platform and developing analogs from noroxymorphone and proenkephalin, Cleveland BioLabs aims to treat numerous conditions, including cancer, inflammatory disorders, autoimmune diseases, and infectious diseases. Additionally, the brand has developed the CYTO-200 and CYTO-400 platforms, which are therapies based on noroxymorphone and proenkephalin analogs, respectively. These platforms have shown promising anti-angiogenic and anti-inflammatory properties, opening up new possibilities for fighting diseases.

Cleveland BioLabs utilizes a proprietary drug discovery and development platform known as AIMS™, which allows them to enhance their understanding of the relationship between these analogs and determine their impact on pharmacokinetic-pharmacodynamic relationships, potency, and selectivity. This approach enables them to develop improved therapies that address specific patient needs and elicit immune response levels not achieved by other immunotherapy approaches. Their CYTO-600 TLR5 program focuses on developing analogs to target various indications, such as hematology, acute radiation syndrome, cancer, inflammatory disorders, autoimmune diseases, and infectious diseases.

Specifically, CYTO-600 TLR5 is a recombinant protein that acts as an agonist of toll-like receptor 5 (TLR5), an innate immunity receptor. This activation triggers a powerful innate immune response, leading to the expression of critical genes involved in protection and regeneration. With a commitment to scientific excellence and innovation, Cleveland BioLabs continues to push the boundaries of immunotherapy to improve the lives of patients facing challenging medical conditions